Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

A Pegu, SE O'Connell, SD Schmidt, S O'Dell… - Science, 2021 - science.org
A Pegu, SE O'Connell, SD Schmidt, S O'Dell, CA Talana, L Lai, J Albert, E Anderson
Science, 2021science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over
time. Here, we assess the effect of SARS-CoV-2 variants B. 1.1. 7 (Alpha), B. 1.351 (Beta), P.
1 (Gamma), B. 1.429 (Epsilon), B. 1.526 (Iota), and B. 1.617. 2 (Delta) on binding,
neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by
the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive …
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
AAAS